QIDP

Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

Retrieved on: 
Thursday, October 20, 2022
Biotechnology, Pharmaceutical, Surgery, General Health, Health, Medical Devices, Infectious Diseases, Clinical Trials, LinkedIn, United States Department of Health and Human Services, MIC, MRSA, Cystic Fibrosis Foundation, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Klebsiella, Gram-negative bacteria, Debridement, Human services, Infection, QIDP, Cons, MSSA, Patient, Escherichia coli, Hospital, Research, Twitter, Staphylococcus aureus, Mortality, Inflammation, Enterobacter cloacae, Artificial intelligence, Technology, Solution, Staphylococcus, TKA, Cystic fibrosis, Administration, Department, Gram-positive bacteria, Klebsiella pneumoniae, Drug of last resort, Enterococcus, Enterobacter, Bacteria, MDR, Fast Track, Gram, S. aureus, Surgeon, Cancer, Algorithm, Pharmaceutical industry, Vaccine, Wellcome

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .

Key Points: 
  • Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, is presenting two posters featuring preclinical data from its antimicrobial peptide, PLG0206, at IDWeek 2022 .
  • The studies demonstrate the potent activity of PLG0206 against bacteria that cause periprosthetic joint infections (PJI), including multidrug resistant (MDR) bacteria.
  • PJI is the most common complication of joint replacement surgery and is a life-changing event for patients.
  • MDR related infections pose a significant concern to patients as well as society in both the short- and long-term.

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

Retrieved on: 
Thursday, October 20, 2022
General Health, Pharmaceutical, Health, Clinical Trials, National Institutes of Health, Degenerative disease, QIDP, Infection, Diarrhea, TOC, Genetically modified bacteria, Treatment, Test, Administration, National, Gram-positive bacteria, CEO, Bacteria, Pyelonephritis, MDR, United States Department of Health and Human Services, Urinary tract infection, Biomedical Advanced Research and Development Authority, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gram-negative bacteria, BARDA, Company, Department, Medication, CRE, FDA, AP, National Institute, Hypertension, Constipation, Nausea, Human services, LFU, Cefepime, Headache, Cutis marmorata, Wellcome Trust, New Drug Application, Patient, Food, BLI, Complicated, Adult, National Institute of Allergy and Infectious Diseases, Medical microbiology, Pseudomonas aeruginosa, Melioidosis, Pharmaceutical industry, Antibiotics, Safety, Meropenem

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
  • The presentations, along with the four other posters detailing additional cefepime-taniborbactam data at IDWeek 2022 (see release ), will be available on the companys website.
  • We believe this data is meaningful given the sustained clinical benefit versus meropenem up to 3 to 4 weeks after treatment, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • The safety data for cefepime-taniborbactam was consistent with the historical safety data for cefepime.

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

Retrieved on: 
Monday, October 17, 2022
SAN, U.S. Securities and Exchange Commission, PDUFA, Drug Quality and Security Act, Therapy, ID, Melinta Therapeutics, CDTX, QIDP, NDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Biotechnology, Patient, Organic acid, Prescription Drug User Fee Act, Security (finance), Securities Act of 1933, Private Securities Litigation Reform Act, Food, Securities Exchange Act of 1934, Fungemia, Mycosis, Safety, Respect, GLOBE, DFC (cipher), Forward-looking statement, FDA, COVID-19, Pharmacokinetics, Restore, Pharmaceutical industry, Ciclosporin, EU

QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.

Key Points: 
  • QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.
  • Additionally, rezafungin has been granted Orphan Drug Designation for its use in the treatment of invasive candidiasis in both the U.S. and EU.
  • Cidara retains the rights to rezafungin in Japan and has licensed the commercial rights to Melinta Therapeutics in the U.S. and Mundipharma Medical in all other geographies.
  • Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases.

F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022

Retrieved on: 
Thursday, October 13, 2022
European Medicines Agency, Immunology, Disease, G.H. Raisoni Department of Microbiology and Biotechnology, SOC, Infection, QIDP, Mycosis, Gambat Liver Transplant Unit, Patient, Hematology, Standard of care, Inhalation, Comparison, Mortality, Coccidioidomycosis, Internal medicine, IFI, Company, Department, Transplant, OLO, Safety, GLOBE, Aspergillosis, Antifungal, FDA, UZ Leuven, Human, Pharmaceutical industry, Dentistry, Scopulariopsis, Coccidioides, KU Leuven, Aspergillus

The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.

Key Points: 
  • The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.
  • Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and invasive scedosporiosis.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.
  • Invasive aspergillosis is a rare disease that can occur in over 10% of some high-risk immunosuppressed populations with mortality exceeding 80%.

SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022

Retrieved on: 
Tuesday, October 11, 2022
European Medicines Agency, IA, EMA, Infection, QIDP, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, Patient, IV, IC, FURI, Food, Fungemia, GLOBE, Canker, FDA, Drug of last resort, Tablet, Pharmaceutical industry

Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • In addition, late-stage clinical investigation of oral ibrexafungerp for the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.

Microbion Corporation Announces Data Highlighting Pravibismane's Effect on Bacterial Energetics Presented at ASM Microbe 2022

Retrieved on: 
Tuesday, October 11, 2022
Education, ASM, MRSA, Cystic Fibrosis Foundation, Chronic lung disease, Federal Ministry of Education and Research (Germany), Assistant, MOA, Growth, Biofilm, QIDP, Federal Ministry of Health (Germany), Escherichia coli, Patient, NIH, Staphylococcus aureus, Multimedia, Mycobacterium, NTM, Orphan drug, Company, Department, Investor, US, Intention, Safety, Cooperative, Bacteria, United States Department of Defense, ATP, FDA, Pseudomonas aeruginosa, Poster, Wellcome Trust, Pharmaceutical industry, Research

and VANCOUVER, BC., Oct. 11, 2022 /PRNewswire/ - Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC.

Key Points: 
  • and VANCOUVER, BC., Oct. 11, 2022 /PRNewswire/ - Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC.
  • The poster, titled "Pravibismane's Effect on Bacterial Energetics is Conserved Across Various Bacterial Species" highlights that:
    Pravibismane disrupts bacterial bioenergetics and protein synthesis in planktonic and biofilm phenotypes, contributing to pravibismane's antimicrobial efficacy.
  • With a novel mechanism of action, pravibismane rapidly reduces bacterial ATP production in both planktonic and biofilm bacterial populations, thereby halting global bacterial cellular metabolism.
  • Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Venatorx Pharmaceuticals to Present at IDWeek 2022

Retrieved on: 
Tuesday, October 11, 2022
FDA, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Degenerative disease, Urinary tract infection, New Drug Application, Infection, QIDP, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Gram-negative bacteria, Meropenem, Pyelonephritis, BARDA, Food, Company, Gram-positive bacteria, BLI, Adult, Safety, Tuberculosis verrucosa cutis, Bacteria, CRE, FDA, Pseudomonas aeruginosa, Melioidosis, Pharmaceutical industry, Cefepime

Cefepime-taniborbactam recently completed a Phase 3 study (CERTAIN-1) in adults with complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • Cefepime-taniborbactam recently completed a Phase 3 study (CERTAIN-1) in adults with complicated urinary tract infections (cUTI), including pyelonephritis.
  • In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections.
  • Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections.
  • In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections.

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Friday, October 7, 2022
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Health Technology, Clinical Trials, LinkedIn, ASM, United States Department of Health and Human Services, Cystic Fibrosis Foundation, Disease, Risk, Biomedical Advanced Research and Development Authority, Founders Fund, Development, Infection, Debridement, Human services, Conference, QIDP, Drug development, Society, Patient, Hospital, Twitter, Mortality, Inflammation, Artificial intelligence, European Society of Clinical Microbiology and Infectious Diseases, Technology, Stenotrophomonas maltophilia, Cystic fibrosis, TKA, Administration, Acinetobacter baumannii, Department, Blood, Antimicrobial resistance, Research, Bacteria, Recurrence, Skin, MDR, Fast Track, Challenge, Gram, ESCMID, Pseudomonas aeruginosa, Poster, Algorithm, Vaccine, Pharmaceutical industry, Wellcome

Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.

Key Points: 
  • Peptilogics , a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, presented preclinical data from its peptide, PLG0206, at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance.
  • Data presented demonstrate activity of PLG0206 against multi-drug resistant pathogens and suggest that this novel antimicrobial peptide could potentially address difficult to treat bacterial infections.
  • The poster, titled Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods, highlights data investigating PLG0206 against isolates Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophili present in skin, urinary, blood, intra-abdominal and respiratory infections.
  • PLG0206 has the potential to rapidly target bacteria and persistent pathogens that produce biofilm and evade conventional antibiotics.

Peptilogics Announces First Patient Dosed in Phase 1b Study of PLG0206 for Periprosthetic Joint Infection

Retrieved on: 
Thursday, October 6, 2022
FDA, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, United States Department of Health and Human Services, Cystic Fibrosis Foundation, Disease, Biomedical Advanced Research and Development Authority, Founders Fund, Risk, Development, Infection, Debridement, Human services, QIDP, Patient, Hospital, Federal, Program, Mortality, Inflammation, Artificial intelligence, Technology, Cystic fibrosis, TKA, Administration, Department, Face, Research, Safety, Bacteria, Associate, Recurrence, Fast Track, Hip, Ageing, Failure, Algorithm, Pharmaceutical industry, Wellcome

We believe PLG0206 has the potential to change the treatment paradigm for PJI, said David Huang, M.D., Ph.D, Chief Medical Officer of Peptilogics.

Key Points: 
  • We believe PLG0206 has the potential to change the treatment paradigm for PJI, said David Huang, M.D., Ph.D, Chief Medical Officer of Peptilogics.
  • We are excited to help advance the care of patients who have been diagnosed with prosthetic joint infection.
  • The use of PLG0206, the engineered antimicrobial peptide, allows us to hopefully retain hip and knee replacements while effectively treating the patients infection.
  • PLG0206 is an investigational, broad-spectrum, non-traditional antibiotic peptide therapeutic currently in Phase 1b clinical development for the treatment of periprosthetic joint infection (PJI).

DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in Dublin

Retrieved on: 
Wednesday, October 5, 2022
CDC, Constipation, Epithelium, White Blood Cells, Infection, Clostridioides difficile (bacteria), Feces, QIDP, Virulence, Toxic megacolon, Diarrhea, CDI, Patient, Clostridioides difficile infection, Perforated ulcer, Collection, GI, Subclinical infection, Centers for Disease Control and Prevention, ISIN, Center, Vomiting, Company, Physiology, Gram-positive bacteria, Blood, Disease, Incidence, Bacteria, Recurrence, Vancomycin, Ileus, Intubation, Heart, Global health, FDA, Pharmaceutical industry, Vaccine, Dietary supplement, Antibiotics, Clostridioides

Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.

Key Points: 
  • Preclinical and clinical data show that the prodrug DNV3837 is rapidly converted to DNV3681 in vivo and that the active drug mostly concentrates in the GI tract.
  • The diarrhea episodes improved after 6 days of treatment and came back to normal 10 days after treatment after a transient constipation period.
  • Georges Gaudriault, Chief Scientific Officer of DEINOVE who attended the ESCMID/ASM conference in Dublin specifies: The use of DNV3837 is a potential paradigm shift.
  • Located at the heart of the Euromedecine park in Montpellier, DEINOVE has been listed on EURONEXT GROWTH (ALDEI - code ISIN FR0010879056) since 2010.